ZLJ-6 

ZLJ-6 is a dual COX and 5-LOX inhibitor with oral activity. The IC₅₀ values for COX-1, COX-2 and 5-LOX were 0.73, 0.31 and 0.99 μM, respectively. ZLJ-6 has anti-inflammatory and analgesic activity^[1][1].

ZLJ-6 (3, 10, 30 μM, 6 h) can effectively inhibit the expression of TNF-α-induced monocyte endothelial interaction and adhesion molecules (e-selectin, ICAM-1 and VCAM-1)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ZLJ-6 (3, 10, 30 mg/kg, oral) shows effective anti-inflammatory activity in carrageenan-induced rat plantar edema model, and analgesic activity in acetic acid-induced mouse peritoneal construction model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

375.42

C₁₃H₁₇N₃O₆S₂

1051931-39-5

CS(=O)(O)=O.CN(C(N)=NC/1=O)C1=C/C2=CC=C(C=C2)S(C)(=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Chen L, et al. ZLJ-6, a novel COX/5-LOX inhibitor, attenuates TNF-α-induced endothelial E-selectin, ICAM-1 and VCAM-1 expression and monocyte-endothelial interactions via a COX/5-LOX-independent mechanism. Vascul Pharmacol. 2011 Nov-Dec;55(5-6):135-42.  [Content Brief]

  [2]. Li L, et al. The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor. Eur J Pharmacol. 2009 Apr 1;607(1-3):244-50.  [Content Brief]